zolbetuximab
astellas
[]
zolbetuximab (anti claudin 18.2 antibody) in combination with mfolfox6 significantly improved pfs (hr: 0.751) and os (hr: 0.750) vs mfolfox6 alone in patients with claudin 18.2+ advanced/metastatic gastric or gej adenocarcinoma in the phase 3 spotlight trial (asco gi 23).